Truvada
Drug
Gilead Sciences Inc
Total Payments
$39.6M
Transactions
9,960
Doctors
3,317
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $11,345 | 2 | 0 |
| 2023 | $262,751 | 10 | 0 |
| 2022 | $657,582 | 12 | 0 |
| 2021 | $1.1M | 23 | 2 |
| 2020 | $838,149 | 23 | 1 |
| 2019 | $3.0M | 3,203 | 1,663 |
| 2018 | $3.1M | 3,539 | 1,369 |
| 2017 | $30.6M | 3,148 | 761 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $35.6M | 1,393 | 89.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.8M | 1,315 | 7.2% |
| Travel and Lodging | $547,417 | 1,597 | 1.4% |
| Food and Beverage | $392,433 | 5,575 | 1.0% |
| Consulting Fee | $244,990 | 77 | 0.6% |
| Education | $59.97 | 3 | 0.0% |
Payments by Type
Research
$35.6M
1,393 transactions
General
$4.0M
8,567 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | Gilead Sciences Inc | $29.1M | 1 |
| Promotion and Implementation of HIV PrEP in China: A PrEP demonstration project for at-risk youth in Wuhan and Guangzhou | Gilead Sciences, Inc. | $542,250 | 0 |
| Impact of Nursing Involvement on Implementation of HIV Prevention Services in an Academic OBGYN Clinical Setting | Gilead Sciences, Inc. | $531,760 | 0 |
| Evaluation of Implementation of the Phoenix PrEP Access Project for Youth Aged 13-24 | Gilead Sciences, Inc. | $404,464 | 0 |
| Expanding PrEP By Embedding Unannounced SNAPS Navigators in High Sexually Transmitted Infection (STI) Testing Clinical Sites | Gilead Sciences, Inc. | $375,077 | 0 |
| PrEP to Prevent HIV Acquisition in US Women: A Demonstration Project | Gilead Sciences, Inc. | $358,580 | 0 |
| Defining the PrEP care continuum among recently incarcerated men at-risk for HIV | Gilead Sciences, Inc. | $351,829 | 0 |
| Identification of the Pre-exposure Prophylaxis (PrEP) cascade for Women and Integration of PrEP into Women's Family Planning Services: a prospective cohort (Resubmission with revised budget and protocol per committee recommendations) | Gilead Sciences, Inc. | $281,167 | 0 |
| Women Prepping for PrEP Plus (WPPP+) | Gilead Sciences, Inc. | $267,032 | 0 |
| Delivering HIV Pre-Exposure Prophylaxis to Networks of Justice-Involved Women | Gilead Sciences, Inc. | $260,772 | 0 |
| Adult Drug Court (ADC): Understanding Promoters and Barriers to Uptake and Adherence of Oral Truvada for PrEP | Gilead Sciences, Inc. | $249,544 | 0 |
| Sexually-acquired HCV Infections Emerging Among HIV-uninfected Men Who Have Sex with Men on Pre-exposure Prophylaxis Against HIV | Gilead Sciences, Inc. | $221,900 | 0 |
| Pathways to prevention: An observational study of HIV pre-exposure prophylaxis utilization among young transgender women and men who have sex with men in an urban community-based setting | Gilead Sciences, Inc. | $182,126 | 0 |
| Integrating PrEP Screening and Referral into Family Planning Clinics in the Southern U.S. | Gilead Sciences, Inc. | $171,446 | 0 |
| A brief, pragmatic experiment to determine the feasibility of a public-health-partnered tele-pharmacist model for PrEP delivery in a rural state'' | Gilead Sciences, Inc. | $168,841 | 0 |
| Reducing HIV risk among South African women during conception, pregnancy, and postpartum | Gilead Sciences, Inc. | $158,581 | 0 |
| Epidemiology of HIV risk and prevention needs in trans masculine adults who have sex with cisgender males (TMSM) | Gilead Sciences, Inc. | $151,435 | 0 |
| A phase IV open-label evaluation of safety, tolerability, and acceptability of a fixed-dose formulation of bictegravir , emtricitabine, and tenofovir alafenamide for nPEP | Gilead Sciences, Inc. | $148,764 | 0 |
| Understanding substance use and incident HIV/STI among young black MSM | Gilead Sciences, Inc. | $122,366 | 0 |
| HIV Pre-exposure Prophylaxis Linkage and Adherence in Men who have Sex with Men following Completion of a PrEP Demonstration Project. | Gilead Sciences, Inc. | $120,017 | 0 |
Top Doctors Receiving Payments for Truvada
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| James Bowerman | — | Scottsdale, AZ | $35.0M | 1,388 |
| , M.D | Internal Medicine | Seattle, WA | $606,300 | 60 |
| , D.O | Family Medicine | Berkley, MI | $137,472 | 172 |
| , M.D | Family Medicine | Austin, TX | $135,663 | 149 |
| , M.D | Family Medicine | Seattle, WA | $118,690 | 162 |
| , MD | Internal Medicine | Washington, DC | $103,831 | 142 |
| , M.D | Infectious Disease | Los Angeles, CA | $90,152 | 78 |
| , MD, MPH | Internal Medicine | San Francisco, CA | $81,428 | 111 |
| , M.D | Infectious Disease | San Antonio, TX | $81,147 | 149 |
| , D.O | Geriatric Medicine | Phoenix, AZ | $80,385 | 114 |
| , M.D., M.P.H | Internal Medicine | Jonesboro, GA | $80,306 | 115 |
| , D.O | Family Medicine | Oakland Park, FL | $78,192 | 81 |
| , DO | Internal Medicine | Stamford, CT | $75,686 | 80 |
| , MD | Adult Medicine | Washington, DC | $75,670 | 73 |
| , M.D | Family Medicine | Los Angeles, CA | $60,646 | 85 |
| , MD | Infectious Disease | New Haven, CT | $59,714 | 58 |
| , DO | Family Medicine | Columbus, OH | $58,343 | 72 |
| , MD | Internal Medicine | Smithtown, NY | $57,308 | 51 |
| , M.D | Internal Medicine | Oakland, CA | $56,562 | 66 |
| , MD | Infectious Disease | San Diego, CA | $52,207 | 60 |
| , M.D | Family Medicine | Johnston, RI | $52,064 | 49 |
| , M.D | Gastroenterology | Washington, DC | $50,992 | 57 |
| , MD | Internal Medicine | New York, NY | $48,571 | 82 |
| , M.D | Internal Medicine | Miami Beach, FL | $47,090 | 47 |
| , M.D | Emergency Medicine | Jackson, MS | $43,498 | 58 |
Ad
Manufacturing Companies
- Gilead Sciences Inc $30.6M
- Gilead Sciences, Inc. $9.0M
Product Information
- Type Drug
- Total Payments $39.6M
- Total Doctors 3,317
- Transactions 9,960
About Truvada
Truvada is a drug associated with $39.6M in payments to 3,317 healthcare providers, recorded across 9,960 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2024. In 2024, $11,345 was paid across 2 transactions to 0 doctors.
The most common payment nature for Truvada is "Unspecified" ($35.6M, 89.8% of total).
Truvada is associated with 20 research studies, including "A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection" ($29.1M).